# Afatinib in Patients with Fanconi Anemia (FA) and Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)

> **NCT06648096** · PHASE1,PHASE2 · RECRUITING · sponsor: **Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau** · enrollment: 25 (estimated)

## Conditions studied

- Fanconi Anemia
- Head and Neck Squamous Cell Carcinoma

## Interventions

- **DRUG:** Afatinib

## Key facts

- **NCT ID:** NCT06648096
- **Lead sponsor:** Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-08
- **Primary completion:** 2028-12
- **Final completion:** 2028-12
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2024-11-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06648096

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06648096, "Afatinib in Patients with Fanconi Anemia (FA) and Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06648096. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*